TickerFacts.

Tonix Pharmaceuticals Holding Corp. (TNXP): Revenue

Annual figures by period end, from SEC filings.

$13.11M
Year ended 2025-12-31
$29.10M
Trailing 12 months to 2026-06-30
2023-12-31: $7.77M2024-12-31: $10.09M2025-12-31: $13.11M$13.11M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$13.11M+29.8%2026-03-12, From 2025-01-01
2024-12-31$10.09M+29.9%2026-03-12, From 2024-01-01
2023-12-31$7.77Mn/a2025-03-18, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$13.11M+29.8%
Evommune, Inc. (EVMN)2025-12-31$13.00M+85.7%
CV Sciences, Inc. (CVSI)2025-12-31$13.79M-12.2%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$12.45M-25.2%
Pyxis Oncology, Inc. (PYXS)2025-12-31$13.86M-14.2%
Arbutus Biopharma Corp (ABUS)2025-12-31$14.08M+128.2%
Prelude Therapeutics Inc (PRLD)2025-12-31$12.14M+73.4%
Opus Genetics, Inc. (IRD)2025-12-31$14.20M+29.1%
Jaguar Health, Inc. (JAGX)2025-12-31$11.51M-1.5%

Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗